| Market Cap | 236.54M | P/E | - | EPS this Y | 8.30% | Ern Qtrly Grth | - |
| Income | -21.49M | Forward P/E | -8.18 | EPS next Y | -18.20% | 50D Avg Chg | 1.00% |
| Sales | 8.95M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 2.00% |
| Dividend | N/A | Price/Book | 3.36 | EPS next 5Y | - | 52W High Chg | -22.00% |
| Recommedations | 2.00 | Quick Ratio | 2.02 | Shares Outstanding | 188.53M | 52W Low Chg | 36.00% |
| Insider Own | 4.13% | ROA | -11.80% | Shares Float | 139.57M | Beta | 1.33 |
| Inst Own | 44.03% | ROE | -32.07% | Shares Shorted/Prior | 10.40M/9.62M | Price | 1.39 |
| Gross Margin | 92.50% | Profit Margin | -240.20% | Avg. Volume | 776,882 | Target Price | 5.20 |
| Oper. Margin | -135.63% | Earnings Date | May 9 | Volume | 270,254 | Change | -2.11% |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
| HC Wainwright & Co. | Buy | Mar 8, 24 |
| HC Wainwright & Co. | Buy | Feb 13, 24 |
| Cantor Fitzgerald | Overweight | Feb 5, 24 |
| HC Wainwright & Co. | Buy | Aug 11, 23 |
| Cantor Fitzgerald | Overweight | Jul 25, 23 |
| HC Wainwright & Co. | Buy | Jul 24, 23 |
| HC Wainwright & Co. | Buy | May 12, 23 |
| HC Wainwright & Co. | Buy | Apr 26, 23 |
| HC Wainwright & Co. | Buy | Mar 10, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Jayasuriya Anula | Director Director | Dec 29 | Buy | 1.09 | 10,000 | 10,900 | 10,000 | 01/02/24 |
| Culley Brian M | President and CEO President and CEO | Mar 25 | Buy | 1.38 | 5,250 | 7,245 | 81,280 | 03/28/22 |
| BROADWOOD PARTNERS, L.P. | Director Director | Mar 23 | Buy | 0.71 | 930,106 | 660,375 | 34,935,485 | 03/25/22 |
| Mulroy Michael H. | Director Director | Mar 24 | Buy | 1.40 | 7,000 | 9,800 | 258,555 | 03/25/22 |
| Hogge Gary S. | SVP,Clinical & Medic.. SVP,Clinical & Medical Affairs | Dec 28 | Option | 1.16 | 510,838 | 592,572 | 37,695 | 12/30/21 |
| Hogge Gary S. | SVP,Clinical & Medic.. SVP,Clinical & Medical Affairs | Dec 28 | Sell | 2.46 | 539,283 | 1,326,636 | 12/30/21 | |
| Hernandez Alexandra | Sr Director Finance/.. Sr Director Finance/Controller | Apr 01 | Option | 0.69 | 6,000 | 4,140 | 6,000 | 04/01/21 |
| Hernandez Alexandra | Sr Director Finance/.. Sr Director Finance/Controller | Apr 01 | Sell | 2.23 | 6,000 | 13,380 | 04/01/21 | |
| Culley Brian M | President and CEO President and CEO | Apr 01 | Option | 2.35 | 15,450 | 36,308 | 201,052 | 04/01/21 |
| Culley Brian M | President and CEO President and CEO | Dec 31 | Option | 1.76 | 15,450 | 27,192 | 190,945 | 12/31/20 |